One platform connecting startups, corporations, research institutions, regions and investors
Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE
1. Technology overview
Ultromics (legal entity Ultromics Limited) develops AI for cardiology, founded by Ross Upton (CEO) and Prof. Paul Leeson (CMO) with links to Oxford University. It focuses on finding disease signals in routine echocardiograms.
The EchoGo platform runs on standard echo images without new hardware: EchoGo Heart Failure helps identify HFpEF, EchoGo Amyloidosis screens for cardiac amyloidosis, and EchoGo Score adds probability scoring. It connects to ultrasound systems and PACS through secure cloud infrastructure. The company reports more than 430,000 echocardiograms analyzed.
2. Highlighted features & specifications
- EchoGo Heart Failure: Diagnostic aid for identifying HFpEF from echocardiograms.
- EchoGo Amyloidosis: Screening aid for cardiac amyloidosis with Breakthrough Device Designation.
- EchoGo Score: Adds probability scoring for risk prioritization.
- Cloud platform: Secure processing connected to ultrasound systems and PACS.
- Evidence base: Validated across 25 peer-reviewed studies per the company.
3. Potential application
Large Vietnamese cardiology centers can evaluate HFpEF screening on existing echo archives. Research hospitals can run amyloidosis case-finding studies. Medical device distributors can explore partnership for the Southeast Asian market.
4. Benefits
Detects HFpEF and cardiac amyloidosis from echo studies that are already acquired.
No new hardware or workflow disruption, as it plugs into ultrasound systems and PACS.
EchoGo Heart Failure improved HFpEF detection by 73.6% versus standard clinical risk scores (company figure).
Holds FDA 510(k), ISO 13485 and ISO 27001, with Medicare reimbursement in the U.S.
5. Market trends & opportunities
Heart failure with preserved ejection fraction and cardiac amyloidosis are frequently under-diagnosed, and AI on routine echo is emerging as a screening layer. The company's current commercial push is U.S.-focused, so Southeast Asian availability would depend on future partnerships.
6. Other information
Legal entity Ultromics Limited (HQ location not stated on fetched pages). Series C of USD 55M announced 31 July 2025 with Oxford Science Enterprises, GV and Blue Venture Fund among backers. CPT Category III code 0932T assigned to EchoGo Heart Failure.
